Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. …
Immutep and Monash announce first publication detailing how human LAG-3 Binds to MHC Class II
December 16, 2024 Australian Biotech
Latest Video
New Stories
-
Immutep and Monash announce first publication detailing how human LAG-3 Binds to MHC Class II
December 16, 2024 - - Australian Biotech -
'They intended to launch a product on the market when that was not their intention'
December 16, 2024 - - BioPharma -
'The demand has been higher than expected, and we’ve worked hard to make sure that it remains affordable'
December 16, 2024 - - Latest News -
Auditor General set to table long-awaited PBS performance audit
December 15, 2024 - - Latest News -
The 'Week in Review' Podcast - 13 December
December 13, 2024 - - Podcast -
Report shows that weight is now the leading risk factor for Australia's disease burden
December 13, 2024 - - Latest News -
RACGP calls for free Meningococcal B vaccination program for Western Australia
December 12, 2024 - - Latest News